UNLOXCYT J Code: J9275

Drug & Product Overview

HCPCS Descriptor Injection, cosibelimab-ipdl, 2 mg

HCPCS Added Date July 1, 2025

Manufacturer Sun Pharma

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Form Injection, Solution

About UNLOXCYT

Unloxcyt is a medication aligned to the HCPCS J Code: J9275 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Sun Pharma.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
70095-0130-01	Unloxcyt	Sun Pharmaceutical Industries, Inc.	150	300 MG / 5 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

UNLOXCYT Pricing & Reimbursement

J9275 Private Payer Reimbursement

$22.19 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

UNLOXCYT CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

UNLOXCYT Medically Unlikely Edits (MUE)

The most billing units of J9275 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 2 mg.

Practitioner Office & Hospital Outpatient

600 units / day

= 1,200 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

UNLOXCYT Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC)

Drug Class

AntibodiesMonoclonal [CS]Programmed Death Ligand-1 Antagonists [MoA]Programmed Death Ligand-1 Blocker [EPC]Programmed Death Ligand-1-directed Antibody Interactions [MoA]

Frequently Asked Questions

Is there an available UNLOXCYT billing and coding guide?

Our team has not identified a manufacturer-source of billing and coding information for UNLOXCYT. Please reach out to our team if this is a mistake.

Are there any available UNLOXCYT patient assistance programs?

Our team has not identified a source of patient assistance information for UNLOXCYT. Please reach out to us if this is a mistake.

Where can I find UNLOXCYT prescribing information?

UNLOXCYT prescribing information can be found at the link below. Visit Here →

Where can I find UNLOXCYT side effect information?

Side effect information for UNLOXCYT can be found through MedlinePlus. Visit Here →

Does billing UNLOXCYT require JZ/JW wastage modifiers?

CMS does not include UNLOXCYT (J9275) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J9275. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.